Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored IV fluids aim to shield kidneys during heart tests

NCT ID NCT04936607

Prevention Sponsor: Montreal Heart Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized hydration strategy to prevent contrast-induced acute kidney injury (CI-AKI) in adults undergoing coronary angiogram or PCI. Participants receive intravenous saline at rates adjusted based on their heart pressure, contrast dose, and kidney function. The goal is to see if this tailored approach reduces kidney damage and improves overall outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Personalized hydration strategy (intravenous saline adjusted based on heart pressure, contrast dose, and kidney function)
What this could lead to
If successful, this could provide a simple, tailored hydration method to reduce the risk of kidney injury after common heart procedures.
What could go wrong
This is an early-stage trial (Phase NA) with 1158 participants, so results may not apply to all patients. The hydration adjustments are complex and may not prevent kidney injury in everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,158 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2021

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * Planned coronary angiogram and/or PCI; * Willingness to participate and to attend study visits; * Expected life expectancy ≥6 months. Exclusion Criteria: * Cardiogenic or non-cardiogenic shock at the time of the procedure; * Emergent procedures (e.g. STEMI); * Iodine-based contrast media received within 2 days; * Presence of Intra-Aortic Balloon Pump (IABP); * Cardiac arrest within 24 hours; * Pre-procedural AKI defined using the modified KDIGO criteria within 7 days; * Renal replacement therapy; * Severe aortic or mitral disease; * LVEF \<30%.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contrast induced acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contrast induced acute kidney injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Montreal Heart Institute

    RECRUITING

    Montreal, Quebec, H1T1C8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.